Convertible Loan Note Extension & RPT

1 July 2025

TruSpine Technologies plc

("TruSpine" or the "Company")

Convertible Loan Note Extension & Related Party Transaction

TruSpine Technologies Plc, the medical device company focused on the spinal (vertebral) stabilisation market, announces that further to the announcement on 24 July 2024, the Company has extended the maturity date of the convertible loan note ("CLN") to 30 June 2026. All other terms of the CLN remain unchanged.

Following the announcement of 23 May 2023, Axis MedTech (Holdings) Limited ("Axis") holds £136,573 of CLNs. Geoff Miller and Sam Ogunsalu, both directors of the Company, are directors and shareholders of Axis as at the date of this announcement.

Related Party Transaction

The extension of maturity date of the CLN (the "Transaction") is a related party transaction for the purposes of Rule 4.6 of the AQSE Growth Market Access Rulebook, by virtue of the Company and Geoff Miller, Non-executive Chairman of the Company, and Sam Ogunsalu, Non-executive Director of the Company, being each a party to the CLN. The director of TruSpine independent of the Transaction, Victoria Sena, confirms that, having exercised reasonable care, skill and diligence, the Transaction is fair and reasonable insofar as the shareholders of TruSpine are concerned.

This announcement contains inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

-END-